VSTM Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Verastem Inc (VSTM) is not a strong buy at the moment for a beginner investor with a long-term strategy. While there are some positive catalysts such as increased hedge fund interest and favorable analyst ratings, the technical indicators and financial performance do not strongly support an immediate buy decision. The stock's bearish moving averages, neutral RSI, and lack of significant recent news or congress trading activity suggest a cautious approach. Additionally, the company's financials show improvement in net income and EPS but remain negative overall, which may not align with a beginner's risk tolerance.
The technical indicators for VSTM show a bearish trend with moving averages (SMA_200 > SMA_20 > SMA_5). The RSI is neutral at 37.283, and the MACD histogram is positive but contracting at 0.0234. Key support and resistance levels are S1: 5.588, Pivot: 5.907, and R1: 6.226. The stock is trading below the pivot level, indicating potential resistance ahead.
Hedge funds are significantly increasing their holdings, with a 1120.13% increase in buying activity over the last quarter. Analysts have raised price targets to $18, citing underappreciated aspects of the company's KRAS franchise.
The stock has bearish moving averages and lacks significant recent news or congress trading activity. Financial performance, while improving, still shows negative net income and EPS. Gross margin has also declined YoY.
In Q3 2025, revenue remained flat YoY at $11.24M. Net income improved significantly YoY but remains negative at -$98.52M. EPS improved to -1.35, up 125% YoY, but still negative. Gross margin dropped to 82.57%, down 17.43% YoY.
Analysts are positive on the stock, with recent upgrades in price targets to $18 and buy ratings from Mizuho and H.C. Wainwright. Guggenheim maintains a buy rating despite discontinued development of a specific drug combination, as it was not a significant component of the stock's valuation.
